Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.

Bernard Escudier; Camillo Porta; Petri Bono; Thomas Powles; Tim Eisen; Cora N Sternberg; Jürgen E Gschwend; Ugo De Giorgi; Omi Parikh; Robert Hawkins; Emmanuel Sevin; Sylvie Négrier; Sadya Khan; Jose Diaz; Suman Redhu; Faisal Mehmud; David Cella

首页> 外文期刊>Journal of Clinical Oncology >Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.

【24h】

Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.

机译：随机，受控，双盲，交叉试验评估Pazopanib对肾病患者的Pazopanib对阳光细胞癌的治疗偏好：双鱼座研究。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

This innovative cross-over trial demonstrated a significant patient preference for pazopanib over sunitinib, with HRQoL and safety as key influencing factors.

机译：这种创新的交叉审判表明，Pazopanib对Sunitinib的显着患者偏好，以及HRQOL和安全作为关键影响因素。

著录项

来源
《Journal of Clinical Oncology》 |2014年第14期|共7页
作者
Bernard Escudier; Camillo Porta; Petri Bono; Thomas Powles; Tim Eisen; Cora N Sternberg; Jürgen E Gschwend; Ugo De Giorgi; Omi Parikh; Robert Hawkins; Emmanuel Sevin; Sylvie Négrier; Sadya Khan; Jose Diaz; Suman Redhu; Faisal Mehmud; David Cella;
展开▼
作者单位

Bernard Escudier Institut Gustave Roussy Villejuif;

Emmanuel Sevin Centre Fran?ois Baclesse;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. [J] . Bernard Escudier, Camillo Porta, Petri Bono, Journal of Clinical Oncology . 2014,第14期

机译：随机，受控，双盲，交叉试验评估Pazopanib对肾病患者的Pazopanib对阳光细胞癌的治疗偏好：双鱼座研究。
2. Patient Preference Between Pazopanib (Paz) and Sunitinib (Sun): Results of a Randomized Double-Blind; Placebo-Controlled, Cross-Over Study in Patients With Metastatic Renal Cell Carcinoma (mRCC)-PISCES Study NCT 01064310 [J] . Clinical advances in hematology & oncology: H&O . 2012,第Suppla15期

机译：Pazopanib（Paz）和Sunitinib（Sun）之间的患者偏好：随机双盲的结果;转移性肾细胞癌（mRCC）患者的安慰剂对照，交叉研究-PISCES研究NCT 01064310
3. Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial [J] . Choueiri Toni K., Figueroa David J., Fay Andre P., Clinical cancer research: an official journal of the American Association for Cancer Research . 2015,第5期

机译：接受舒尼替尼或帕唑帕尼的肾细胞癌患者PD-L1肿瘤表达与治疗结果的相关性：COMPARZ的一项随机对照试验结果
4. Designing Phase III Trials in Metastatic Renal Cell Carcinoma: What Are the New Standards? [C] . Ana M. Molina Genitourinary Cancers Symposium . 2012

机译：在转移性肾细胞癌中设计III期试验：新标准是什么？
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial [O] . Jun Guo, Jie Jin, Mototsugu Oya, 2018

机译：帕唑帕尼和舒尼替尼在未治疗的转移性肾细胞癌患者中的安全性：COMPARZ试验的亚洲与非亚洲亚组分析
7. Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial [O] . Jun Guo, Jie Jin, Mototsugu Oya, 2018

机译：Pazopanib和Sunitinib在治疗 - 天真的转移性肾细胞癌患者中的安全性：亚洲与非亚洲亚群分析的比赛试验

Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.

摘要

著录项

相似文献

相关主题

期刊订阅